THE INFLUENCE OF HIV INFECTION DURATION BEFORE ANTIRETROVIRAL THERAPY ON IMMUNOLOGICAL TREATMENT FAILURE
- Authors: Oleynik A.F.1, Fazylov V.K.1
-
Affiliations:
- Kazan State Medical University
- Issue: Vol 62, No 3 (2017)
- Pages: 114-119
- Section: ORIGINAL RESEARCH
- URL: https://journal-vniispk.ru/0507-4088/article/view/117926
- DOI: https://doi.org/10.18821/0507-4088-2017-62-3-114-119
- ID: 117926
Cite item
Full Text
Abstract
Introduction. Some patients with HIV infection receiving virologically effective antiretroviral therapy (ART) did not show any growth in CD4 cell count during treatment. Despite the long-term treatment of patients, immunodeficiency persisted. Methods. In the observational cohort retro/prospective study we investigated the effect of the duration of HIV infection before starting the antiretroviral therapy on the development of immunological treatment failure. Results. In a group of 140 HIV-infected patients a moderate inverse correlation was found between the duration of HIV infection and CD4 cell gain after 6 months, 1, 2 and 3 years of ART (r = -0.33, p < 0.01; r = -0.3, p < 0.01; r = -0.3, p < 0.01; r = -0.29, p < 0.01, respectively). In the case of ART starting at CD4 count of 200-350 cells/mcl statistically significant differences were revealed in the levels of relative CD4 count at 6 months, 1, 2 and 3 years of ART in sub-groups with durations of HIV infection prior to initiating therapy of 1-8 years and > 8 years (p = 0.035; p = 0.015; p = 0.05; p = 0.05, respectively). In patients who started ART with CD4 levels > 200 cells/mcl after 8 years of HIV infection, the risk of immunological treatment failure is 4 times higher as compared to patients with the same CD4 level, but lesser duration of HIV infection. Conclusions. The shorter the duration of HIV infection, the greater the increase in CD4 cell count. When starting ART at CD4 level of 200-350 cells/mcl, restoration of CD4 count is more intense in the group with lesser period of HIV infection. A negative effect of the >8-year infection duration before the start of ART on the development of the immunological treatment failure was observed in a subgroup with a starting level of CD4 > 200 cells /mcl.
About the authors
A. F. Oleynik
Kazan State Medical University
Author for correspondence.
Email: aalfons@yandex.ru
Russian Federation
V. Kh. Fazylov
Kazan State Medical University
Email: noemail@neicon.ru
Russian Federation
References
- Бартлет Д., Галант Д., Фам П. Клинические аспекты ВИЧ-инфекции. 2009-2010. Пер. с англ. М.: Р. Валент; 2010
- Moore D., Hogg R., Yip B., Wood E., Tyndall M., Braitstein P. et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune Defic. Syndr. 2005; 40: 288-293
- Gilson R.J., Man S.L., Copas A., Rider A., Forsyth A., Hill S. et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborativ HIV Cohort (UK CHIC) Study. HIV Med. 2010; 11: 152-160
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни. 2014; (6): 14-5
- Antiretroviral therapy guidelines, version 7.1. November 2014. European AIDS Clinical Society. Available at: http://arvt.ru/sites/default/files/EACS_Guidelines_v7.1_ENG.pdf
- Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization. Available at: http://www.who.int/hiv/pub/guidelines/en/
- Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/guidelines
- Shmagel K., Smagel N., Saydakova E., Zverev S., Korolevskaya L., Vorobyeva N. et al. Investigation of mechanisms of immunological inefficiency of antiretroviral therapy in HIV-infected patients. In: Proceedings of the ERA.Net RUS Brokerage event. Yekaterinburg; 2011.
- Julg B., Poole D., Ghebremichael M., Castilla C., Altfeld M., Sunpath H. et al. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012; 7(2): 1-5.
- Blanco J.R., Jarrín I., Vallejo M., Berenguer J., Solera C., Rubio R. et al. Definition of advanced age in HIV infection: looking for an age cut-off. AIDS Res. Hum. Retroviruses. 2012; 28(9): 1000-6.
- Grabar S., Kousignian I., Sobel A., Le Bras P., Gasnault J., Enel P. et al. Immunological and clinical responses to Highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004; (18): 2029-38.
- Hoover D.R. Would confirmatory retesting of CD4+ cells to verify AIDS status be too expensive? J. Acquir. Immune Defic. Syndr. 1993; 6(5): 537-9.
- Deeks S.G., Kithen C.M., Liu L., Guo H., Gascon R., Narváez AB., et al. Immune activation see point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004; 104(4): 942-7.
- Фазылов В.Х., Манапова Э.Р., Гольц М.Л., Бешимов А.Т. Клинико-иммунологический и цитокиновый профиль у пациентов ВИЧ-инфекцией на ранних сроках заболевания при различных путях инфицирования. Цитокины и воспаление. 2013; 12(3): 35-40
- Hunt P.W., Brenchley J., Sinclair E., McCune J.M., Roland M., Shafer KP. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 2008; 197(1): 126-33
Supplementary files
